title: [A case of recurrent breast carcinoma metastasis successfully treated with S-1 and zoledronic acid therapy].
abstract: We experienced a case of triple-negative recurrent breast carcinoma achieving a significant improvement by oral S- 1, a fluoropyrimidine-class anticancer drug and zoledronic acid(ZOL), a third generation bisphosphonate(BP). / Against metastases to orbital foramen, chest wall and bone, the oral treatment with S-1 was started at 80 mg/day everyday for 4 weeks, followed by a 2-week rest interval as 1 cycle, and ZOL was injected at 4 mg every 4 weeks. After 2 cycles of treatment, the level of tumor markers and tumor sizes became reduced. Twelve cycles after the initiation of the therapy, recrudescence of the metastatic lesions was not recognized, and no other metastases were recognized in any organ. In the course of the treatment, no adverse drug reactions to S-1 occurred in the patient. For treatment of recurrent breast carcinoma, S-1 is considered to be a useful and tolerable anticancer drug, and combination treatment of S-1 and ZOL is thought to be effective.
authors.affiliation: Dept. of Surgery, Tsuchiura Kyodo General Hospita, Japan.
authors.forename: Yuko
authors.initials: Y
authors.lastname: Tanaka
authors.forename: Toshiaki
authors.initials: T
authors.lastname: Kurokawa
authors.forename: Kaida
authors.initials: K
authors.lastname: Arita
authors.forename: Junichi
authors.initials: J
authors.lastname: Kuramochi
authors.forename: Shinsuke
authors.initials: S
authors.lastname: Usui
authors.forename: Akiyo
authors.initials: A
authors.lastname: Matsumoto
authors.forename: Noriaki
authors.initials: N
authors.lastname: Takiguchi
authors.forename: Susumu
authors.initials: S
authors.lastname: Hiranuma
authors.forename: Katsuhiro
authors.initials: K
authors.lastname: Sanada
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood; D001943:Breast Neoplasms / Q000097:blood / Q000000981:diagnostic imaging / Q000188:drug therapy*; D004164:Diphosphonates / Q000627:therapeutic use*; D004338:Drug Combinations; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D008279:Magnetic Resonance Imaging; D009362:Neoplasm Metastasis / Q000188:drug therapy / Q000473:pathology; D010094:Oxonic Acid / Q000627:therapeutic use*; D012008:Recurrence; D005641:Tegafur / Q000627:therapeutic use*; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome; D000077211:Zoledronic Acid
chemical_list: D014408:Biomarkers, Tumor; D004164:Diphosphonates; D004338:Drug Combinations; D007093:Imidazoles; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D000077211:Zoledronic Acid